“…Although there may be differences between HCVcc and patient-derived particles, e.g. in their apolipoprotein composition of viral subpopulations of different densities, as HCVcc-producing hepatocarcinoma cells are impaired at late steps of VLDL biogenesis and production (7,87,88), our study further extends these previous results (28) and underscores the notion that distinct capture molecules are used by the different HCV subpopulations to induce attachment to target cells. Although attachment of HCVcc of intermediate density, particularly, seems to be mediated by SR-BI, we found that the infectivity of low density HCVcc particles also involves a VLDL-derived component as it could be competed by VLDL and/or by purified apoE.…”